New data reinforces AstraZeneca and Sanofi's nirsevimab as effective RSV immunisation

Nirsevimab is the first investigational immunisation designed to protect all infants across the RSV season with a single dose - News - PharmaTimes

Related Keywords

United Kingdom ,Peric Sim ,Astrazeneca ,Uc Denver School Of Medicine ,Mene Pangalos ,Iusv ,Nirsevimab ,